ECSP19000157A - Conjugados de anticuerpo y fármaco anti-egfr - Google Patents

Conjugados de anticuerpo y fármaco anti-egfr

Info

Publication number
ECSP19000157A
ECSP19000157A ECSENADI2019157A ECDI201900157A ECSP19000157A EC SP19000157 A ECSP19000157 A EC SP19000157A EC SENADI2019157 A ECSENADI2019157 A EC SENADI2019157A EC DI201900157 A ECDI201900157 A EC DI201900157A EC SP19000157 A ECSP19000157 A EC SP19000157A
Authority
EC
Ecuador
Prior art keywords
antibody
conjugates
egfr
egfr drug
drug
Prior art date
Application number
ECSENADI2019157A
Other languages
English (en)
Inventor
Milan Bruncko
Andrew S Judd
Andrew Phillips
Erwin R Boghaert
Andrew J Souers
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of ECSP19000157A publication Critical patent/ECSP19000157A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a conjugados de anticuerpo y fármaco (ADC) anti-receptor del factor de crecimiento epidérmico (EGFR) que inhiben Bcl-xL, incluyendo composiciones y métodos de uso de dichos ADC.
ECSENADI2019157A 2016-06-08 2019-01-03 Conjugados de anticuerpo y fármaco anti-egfr ECSP19000157A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662347416P 2016-06-08 2016-06-08

Publications (1)

Publication Number Publication Date
ECSP19000157A true ECSP19000157A (es) 2019-01-31

Family

ID=59078219

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI2019157A ECSP19000157A (es) 2016-06-08 2019-01-03 Conjugados de anticuerpo y fármaco anti-egfr

Country Status (21)

Country Link
US (3) US20190343961A1 (es)
EP (2) EP3468996B1 (es)
JP (4) JP2019521106A (es)
KR (2) KR20230035690A (es)
CN (4) CN116059202A (es)
AU (2) AU2017277517A1 (es)
BR (1) BR112018075636A2 (es)
CA (1) CA3027178A1 (es)
CL (2) CL2018003527A1 (es)
CO (1) CO2018013497A2 (es)
CR (1) CR20180614A (es)
DO (2) DOP2018000272A (es)
EC (1) ECSP19000157A (es)
IL (3) IL308054A (es)
MX (2) MX2018015286A (es)
PE (1) PE20190512A1 (es)
PH (2) PH12022553314A1 (es)
RU (1) RU2018147224A (es)
SG (2) SG11201810970WA (es)
TW (3) TW202320860A (es)
WO (1) WO2017214282A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109562190A (zh) * 2016-06-08 2019-04-02 艾伯维公司 抗egfr抗体药物偶联物
US20190153107A1 (en) * 2016-06-08 2019-05-23 Abbvie Inc. Anti-egfr antibody drug conjugates
PL3458479T4 (pl) 2016-06-08 2021-07-26 Abbvie Inc. Przeciwciała anty-b7-h3 i koniugaty przeciwciało-lek
CN111065623B9 (zh) * 2017-05-24 2024-10-25 德克萨斯州大学系统董事会 用于抗体药物缀合物的接头
CN113853219B (zh) * 2019-05-20 2025-01-07 诺华股份有限公司 具有包含亲水性基团的接头的抗体药物缀合物
WO2020236825A2 (en) 2019-05-20 2020-11-26 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
RU2745738C1 (ru) 2019-05-20 2021-03-31 МэбПлекс Интернэшнл Ко., Лтд. Однореакторный способ получения промежуточного продукта конъюгата антитело-лекарственное средство
KR102787433B1 (ko) 2020-01-30 2025-03-27 성균관대학교산학협력단 면역관문 억제제 및 엑소좀 분비 억제제를 포함하는 항체-약물 접합체 및 이를 포함하는 약학적 조성물
HRP20240979T1 (hr) * 2020-05-19 2024-10-25 Les Laboratoires Servier Para-amino-benzil povezivači, postupak njihove pripreme i njihova upotreba u konjugatima
AU2021386367A1 (en) 2020-11-24 2023-06-22 Les Laboratoires Servier Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
UY39610A (es) * 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2022231996A1 (en) * 2021-04-26 2022-11-03 The Regents Of The University Of California Combination therapy for treating glioblastoma
KR20240024061A (ko) * 2021-06-22 2024-02-23 리제너론 파마슈티칼스 인코포레이티드 항-EGFRvIII 항체 약물 접합체 및 이의 용도
CN117580846A (zh) * 2022-04-29 2024-02-20 石药集团中奇制药技术（石家庄）有限公司 具有肝靶向递送效应的化合物及其寡聚核苷酸缀合物
WO2023223097A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody drug conjugates
CR20240553A (es) 2022-05-20 2025-05-02 Servier Lab Conjugados de anticuerpo-fármaco de compuestos antineoplásicos y métodos de uso de los mismos
CN118873678A (zh) 2023-01-18 2024-11-01 泰励生物科技（上海）有限公司 抗体偶联药物及其用途
IL322700A (en) 2023-03-10 2025-10-01 Novartis Ag Antibody-drug conjugates that inhibit fennerase and methods of using them
EP4593885B1 (en) 2023-04-18 2026-04-01 Astrazeneca AB Conjugates comprising cleavable linkers
WO2025078841A2 (en) 2023-10-11 2025-04-17 Antikor Biopharma Limited Antibodies, conjugates, and uses thereof
KR20250148505A (ko) 2024-04-04 2025-10-14 주식회사 크로스포인트테라퓨틱스 인간 항체 Fc 변이체 포함 항체-약물 접합체 및 그 용도
WO2026037394A1 (zh) * 2024-08-16 2026-02-19 石药集团巨石生物制药有限公司 一种抗体药物偶联物及其用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1726514A (en) 1926-11-01 1929-08-27 Firm Ferd Liebschner & Sohn Picker for looms
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
DE68921982T4 (de) 1988-06-14 1996-04-25 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP1071700B1 (en) 1998-04-20 2010-02-17 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP2264166B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
KR100787073B1 (ko) 2000-06-28 2007-12-21 글리코파이, 인크. 변형된 당단백질의 제조방법
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US20040192898A1 (en) 2001-08-17 2004-09-30 Jia Audrey Yunhua Anti-abeta antibodies
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
DK2357006T3 (en) 2002-07-31 2015-12-21 Seattle Genetics Inc Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US20050271615A1 (en) 2002-08-30 2005-12-08 Doron Shabat Self-immolative dendrimers releasing many active moieties upon a single activating event
EP1560599A1 (en) 2002-11-14 2005-08-10 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
EP2289559B1 (en) 2003-02-20 2014-02-12 Seattle Genetics, Inc. Anit-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
AU2005233387B2 (en) 2004-04-15 2011-05-26 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
PL1912671T3 (pl) 2005-07-18 2018-02-28 Seattle Genetics, Inc. Koniugaty beta-glukuronid-linker-lek
JP5346589B2 (ja) 2006-02-02 2013-11-20 シンタルガ・ビーブイ 水溶性ｃｃ−１０６５類似体及びその接合体
NZ600039A (en) 2007-11-28 2013-11-29 Mersana Therapeutics Inc Biocompatible biodegradable fumagillin analog conjugates
US20100152725A1 (en) 2008-12-12 2010-06-17 Angiodynamics, Inc. Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation
WO2010138719A1 (en) 2009-05-28 2010-12-02 Mersana Therapeutics, Inc. Polyal drug conjugates comprising variable rate-releasing linkers
WO2011120053A1 (en) 2010-03-26 2011-09-29 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
US8889675B2 (en) * 2011-10-14 2014-11-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI571466B (zh) * 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
MX2014006739A (es) 2011-12-05 2015-06-05 Igenica Biotherapeutics Inc Conjugados de anticuerpo-farmaco y compuestos relacionados, composiciones , y metodos.
IN2014MN01488A (es) 2011-12-23 2015-04-17 Mersana Therapeutics Inc
WO2013173337A2 (en) 2012-05-15 2013-11-21 Seattle Genetics, Inc. Self-stabilizing linker conjugates
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
US20140017265A1 (en) 2012-07-05 2014-01-16 Mersana Therapeutics, Inc. Terminally Modified Polymers and Conjugates Thereof
US10226535B2 (en) 2012-12-10 2019-03-12 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
WO2014093394A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP2931316B1 (en) 2012-12-12 2019-02-20 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
TW202330606A (zh) * 2014-03-21 2023-08-01 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
JP2018502839A (ja) * 2014-12-09 2018-02-01 アッヴィ・インコーポレイテッド Ｂｃｌ−ｘＬ阻害性化合物およびこれを含む抗体薬物コンジュゲート
EP3230282A1 (en) * 2014-12-09 2017-10-18 AbbVie Inc. Bcl xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same
BR112017012377A2 (pt) * 2014-12-09 2018-04-24 Abbvie Inc conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula

Also Published As

Publication number Publication date
TW202423486A (zh) 2024-06-16
MX2022007807A (es) 2022-07-19
SG10201914060WA (en) 2020-03-30
JP2023166395A (ja) 2023-11-21
EP3468996A1 (en) 2019-04-17
SG11201810970WA (en) 2019-01-30
US20250213685A1 (en) 2025-07-03
BR112018075636A2 (pt) 2019-04-09
JP2019521106A (ja) 2019-07-25
CN116059202A (zh) 2023-05-05
CL2018003527A1 (es) 2019-03-15
IL308054A (en) 2023-12-01
US20190343961A1 (en) 2019-11-14
KR20230035690A (ko) 2023-03-14
CN116059394A (zh) 2023-05-05
JP2025032192A (ja) 2025-03-11
RU2018147224A3 (es) 2020-10-14
MX2018015286A (es) 2019-08-12
CO2018013497A2 (es) 2019-02-08
AU2017277517A1 (en) 2019-01-03
CN109563168A (zh) 2019-04-02
WO2017214282A1 (en) 2017-12-14
IL291073A (en) 2022-05-01
PE20190512A1 (es) 2019-04-10
CN116059201A (zh) 2023-05-05
US20230077680A1 (en) 2023-03-16
CR20180614A (es) 2019-07-29
JP2022058351A (ja) 2022-04-12
IL263571A (en) 2019-01-31
PH12022553314A1 (en) 2024-05-27
PH12018502602B1 (en) 2023-08-16
KR20190015526A (ko) 2019-02-13
TW201806626A (zh) 2018-03-01
TW202320860A (zh) 2023-06-01
AU2024205004A1 (en) 2024-08-08
EP4104865A1 (en) 2022-12-21
PH12018502602A1 (en) 2019-09-30
RU2018147224A (ru) 2020-07-14
EP3468996B1 (en) 2022-05-04
CL2019002270A1 (es) 2019-11-15
CA3027178A1 (en) 2017-12-14
DOP2018000272A (es) 2019-01-31
DOP2022000182A (es) 2022-09-30

Similar Documents

Publication Publication Date Title
DOP2022000182A (es) Conjugados de anticuerpo y fármaco anti-egfr
MX2018015280A (es) Conjugados de anticuerpo y farmaco anti-egfr.
PE20211798A1 (es) Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr
MX2018015284A (es) Conjugados de anticuerpo anti-egfr y fármaco.
CL2023001910A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
ECSP19000282A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2018015268A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2018015274A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
PH12018501153A1 (en) Novel anti-claudin antibodies and methods of use
WO2018119351A8 (en) Anti-sez6l2 antibodies and antibody drug conjugates
MX2018005097A (es) Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5.
HK1233205A1 (en) Anti-egfr antibodies and antibody drug conjugates